GlassScriptPhysician profile
Issam A Turk
NPI 1871973420
$13,836.47
in general payments reported to CMS, 2019-2025
28 companies · $9,128 in 2025
The $9,128 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $626 · 2021: $697 · 2022: $1,132 · 2023: $929 · 2024: $115 · 2025: $9,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,200 · Food and Beverage: $1,832 · Travel and Lodging: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,200.00 |
| Food and Beverage | $1,832.17 |
| Travel and Lodging | $1,139.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $8,617.03 | 2023-2025 | |
| Abbvie INC. | $1,758.58 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $511.80 | 2019-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $360.16 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $306.92 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $306.54 | 2019-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.32 | 2019-2023 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $205.30 | 2019-2025 | |
| Merit Medical Systems INC | $198.75 | 2025 | Esophyx |
| Regeneron Healthcare Solutions, INC. | $193.65 | 2022-2025 | Dupixent |
| Ambu INC. | $171.95 | 2020 | |
| Ironwood Pharmaceuticals, INC | $152.47 | 2022-2023 | Linzess |
| Dova Pharmaceuticals | $122.50 | 2019 | |
| Boston Scientific Corporation | $122.15 | 2019 | |
| Evoke Pharma, INC. | $115.38 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $59.52 | 2021-2022 | |
| Pfizer INC. | $58.04 | 2020-2024 | |
| Qol Medical, LLC | $40.43 | 2021-2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $34.15 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $31.93 | 2022 | |
| Ferring Pharmaceuticals INC. | $30.94 | 2023-2024 | Rebyota |
| Ardelyx, INC. | $27.06 | 2022-2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $23.84 | 2022 | |
| Celgene Corporation | $19.48 | 2023 | Zeposia |
| Bayer Healthcare Pharmaceuticals INC. | $17.53 | 2025 | |
| Redhill Biopharma INC. | $16.33 | 2023 | Aemcolo, Movantik, Talicia |
| Alfasigma USA, INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issam Turk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.